TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Evaluation of a Honey Impregnated Dressing at Removing Necrotic Tissue From Chronic Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age~* Subject has a qualified chronic foot or ankle wound, sized 1cm2 to 25 cm2 for ≥ 4 weeks in duration~* Must have necrotic tissue at least 25% of wound area~* The wound type matches one of the indicated wounds listed on the product labeling:~* Leg ulcers~* Pressure ulcers~* Diabetic foot ulcers~* First and second degree burns~* Surgical wounds~* Trauma wounds~* Subject has adequate circulation as demonstrated by biphasic or triphasic Doppler waveform, consistent with adequate blood flow, within 3 months prior to study enrollment. If monophasic on exam, the non-invasive tests must display Ankle Brachial Index over 0.8 and no worse than mild disease on segmental pressures.~* Subject is likely to be compliant with instructions for case, such as following institutional standard of care directions, offloading, and keeping the wound area protected from environmental contaminants~* Type I/II diabetic subjects that meet the following criteria:~* Random blood glucose is less than 450 mg/dL within 30 days of the screening visit~Exclusion Criteria:~* Subject has a known sensitivity or allergy to honey based products, bee venom, or other ingredients in product~* The subject is breastfeeding, pregnant, or has intentions of becoming pregnant during the course of their study participation~* Wound duration ≥ 52 weeks~* The subject has a prognosis that indicated unlikely survival past the study period~* The subject is currently receiving dialysis~* Gangrene is present in the target wound~* Patient's wound is infected~* The subject's diagnosis indicates third degree burns~* The subject has received any treatment prior to study enrollment that may, in the opinion of an Investigator, affect the outcome of the study~* In the opinion of an Investigator, the subject is otherwise not suitable for study participation, such as the subject is likely to be non-compliant with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Honey Impregnated Dressing (Type: EXPERIMENTAL): Honey Impregnated Dressing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult and pediatric (=/\> 2 years old) patients with a diagnosis of acute myelogenous leukemia (including undifferentiated and bi-phenotypic leukemia), or high-risk myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis who will receive first or second anti-leukemia therapeutic intent with chemotherapy, targeted therapy or hypomethylating agents~2. Patients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital.~Exclusion Criteria:~1. Patients with baseline (at start leukemia treatment) infection, defined as patients with a)fever and known positive cultures at the time of randomization; or b) chest or sinus computed tomography with findings suggestive of pneumonia or sinusitis; or c) one positive galactomannan test \>/= 1 or two positive galactomannan text \>/= 0.5 to 1~2. Patients with Zubrod performance status \>/= 3

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Prophylactic Arm) (Type: EXPERIMENTAL): Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
- Arm 2 (Therapeutic Arm) (Type: EXPERIMENTAL): Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Donepezil Memory Preservation Post ECT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of major depressive disorder, anxiety disorders, bipolar depression who are receiving right unilateral ECT will be included.~Exclusion Criteria:~* Patients with previous use of alcohol or illicit drugs within seven days of randomization will be excluded. Preexisting unstable cardiovascular disease including uncontrolled hypertension will be excluded. Patients with a documented allergy to donepezil will also be excluded. Patients with axis I disorders (eg. schizophrenia, schizoaffective disorder) other than major depressive disorder, anxiety disorders and/or bipolar depression will be excluded. Patients on anticoagulant therapy or chronic NSAID therapy will be excluded. Patients who are pregnant or wish to become pregnant within one year from trial enrollment will also be excluded. Patients who have received ECT within 6 months of enrollment will be excluded. Baseline Mini Mental State Examination (MMSE) \< 24 will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- donepezil (Type: ACTIVE_COMPARATOR): Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast or colon cancer~  * Newly diagnosed disease~ * Any stage disease~* Undergoing treatment at the Ireland Cancer Center, University Hospitals Case Medical Center Site~* Scheduled to start a new chemotherapy regimen (objective II only)~* Not concurrently enrolled in a GEM trial (objectives II, III, and IV)~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Understands English~* Menopausal status not specified~PRIOR CONCURRENT THERAPY:~* See Diseases Characteristics

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with cancer (Type: None): Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
- Patients without cancer (Type: None): non-cancer patients, seeking care at out-patient clinics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Active stage TO as determined by symptom onset of under 9 months.~2. Upper eyelid retraction of 1mm or greater in one or both eyes.~3. Complaints of either significant ocular symptoms (despite appropriate use of ocular lubricants), or cosmetic deformity associated with the eyelid retraction.~Exclusion Criteria:~1. Age less than 21 years: due to lack of data on safety for HAG fillers in pediatric population~2. Age over 65 years of age: as HAG filler effect may be different in this population~3. Are pregnant or nursing: as there is little safety data on potential teratogenicity of HAG fillers~4. Have a demonstrated allergy to HAG fillers or lidocaine~5. Have a current infection, skin sore, pimple, rash, hive or cyst over the injection site: to avoid worsening the infection or transmitting it~6. Have a bleeding disorder or currently taking blood thinning medications such as Coumadin, heparin or acetylsalicylic acid on a daily basis.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Unilateral Upper Eyelid Retraction (Type: EXPERIMENTAL): This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection
- Bilateral Upper Eyelid Retraction (Type: EXPERIMENTAL): This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-75 years of age;~* metastatic or advanced gastric cancer;~* disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based chemotherapy for metastatic disease;~* \>=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy;~* \>=1 measurable lesion;~* HER2 overexpression (IHC \[2+\] or \[3+\]).~Exclusion Criteria:~* concurrent chemotherapy or immunotherapy;~* brain or meningeal metastases;~* clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;~* co-existing malignancies or malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ;~* women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: EXPERIMENTAL): Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Research Online Tele-Rehabilitation Program in People After a Stroke Living at Home

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 6-72 months post stroke~* Sitting balance intact (ability to go beyond the midline of the body)~* Moderate impairment of the affected upper extremity determined by range of motion (ROM); shoulder flexion and abduction must be more than 45 degrees with mild to moderate compensations; elbow flexion should be about 45 degrees and trunk movement of about 10 cm.~* Basic ability to independently use the tele-system via touching virtual objects on the screen.~* Having a personal computer (at least Intel i3 processor, with Win7 operating system),Internet access (10MBps) and a large computer monitor (at least 26) at home.~* Caregiver, available when needed, toprovide support throughout the intervention.~Exclusion Criteria:~* Other medical conditions limiting participation in low-intensity exercise training.~* Major receptive aphasia and screening criteria consistent with dementia (Mini-MentalState score \<24).~* Untreated major depression.~* Presence of unilateral spatial neglect as determined by star cancellation (score less than 51).~* Hemianopsia~* Apraxia (limb and ideomotor)~* Other medical conditions that affect the central or peripheral nervous system~* Ataxia

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Single arm study (Type: EXPERIMENTAL): The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years~2. Positive SARS-CoV-2 test by PCR (polymerase chain reaction) or other diagnostic method within the past 7 days~3. Admission to hospital with respiratory symptoms of COVID-19 requiring hospital care and oxygen supplementation (≤ 8L/min)~4. Respiratory symptom onset no more than 7 days prior to hospital arrival~5. Informed consent from the subject or the subject's personal legal representative or a professional legal representative must be available~Exclusion Criteria:~1. Unable to screen, randomize and administer study drug within 48 hours from arrival to hospital~2. Systemic corticosteroid, baricitinib or tofacitinib (or other JAK-STAT signalling pathway inhibitors) therapy within 7 days prior to arrival to hospital or planned for the next days~3. Known hypersensitivity or contraindication to natural or recombinant IFN-beta-1a or its excipients, or to dexamethasone or its excipients~4. Currently receiving IFN-beta-1a therapy~5. Home assisted ventilation (via tracheotomy or non-invasive) except for Continuous Positive Airway Pressure (CPAP) / Bilevel Positive Airway Pressure (BIPAP) used only for sleep-disordered breathing~6. Participation in another concurrent interventional pharmacotherapy trial during the study period~7. Decision to withhold life-sustaining treatment; patient not committed to full support (except DNR after cardiac arrest only)~8. Woman known to be pregnant, lactating or with a positive pregnancy test (urine or serum test)~9. Subject is not expected to survive for 24 hours~10. Subject has liver failure (Child-Pugh grade C)~11. Any clinical condition that in the opinion of the attending clinician or Investigator would present a risk for the subject to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV IFN beta-1a (Type: EXPERIMENTAL): Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
- IV Dexamethasone (Type: ACTIVE_COMPARATOR): Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 and 80 years old~* As per self report and/or medical record female patients are either postmenopausal or not able to become pregnant~* Patients with biopsy proven or suspected non-small cell lung cancer planned to undergo induction chemotherapy and surgery, OR with biopsy proven or suspected non-small cell lung cancer planned to undergo immediate surgical resection~* No clinical/neurological symptoms suggestive of brain metastases by attending's judgment as documented in the medical record and/or correspondence with the research team~* In the judgement of the consenting professional, patient is able to understand English, through verbal and written communication~* Patient is able to undergo MRI scanning (verified with pre-MRI Safety Screening form (Appendix A) used in MSKCC MRI Centers) completed at screening and again prior to having the MRI.~Exclusion Criteria:~* Patients with history of significant neurological diagnoses including stroke, tumor, dementia, epilepsy, or multiple sclerosis as indicated by medical records and/or self report~* History of head injury with evidence of brain injury or loss of consciousness for \> 60 minutes as per EMR or self-report~* No prior treatment with chemotherapy~* Participant has dentures, body jewelry or wig that they are unable to remove as per self-report~* Patient reports that he/she cannot undergo MRI scanning without significant distress or discomfort~* Significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the study (i.e., schizophrenia).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- surgery-only group (Type: None): This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
- induction chemotherapy group (Type: None): This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients must have a diagnosis of relapsed Waldenstrom's Macroglobulinemia.~In addition to the above, key inclusion and exclusion criteria are listed below.~Inclusion Criteria:~1. At least 18 years of age.~2. Agree to use contraception~3. Hemoglobin ≥ 7.5 g/dL, - Absolute neutrophil count ≥ 1.0 x 109/L (1000/mm3), - Platelets ≥ 50,000/μL~Exclusion Criteria:~1. Is nursing or pregnant~2. Has BMI \> 34.9 kg/m2.~3. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg).~4. Receiving chronic systemic corticosteroid therapy \> 20 mg of prednisone daily.~5. Being treated with other anti-cancer therapies (approved or investigational).~6. Has, at the initiation of study drug, received cytotoxic chemotherapy or a Bruton's tyrosine kinase (BTK)-inhibitor (e.g. ibrutinib) within the past 3 weeks or rituximab within the past 2 months~7. Has an active infection requiring systemic antibiotics.~8. Has had surgery requiring general anesthesia within 4 weeks of starting the study.~9. Has autoimmune cytopenia (anemia, thrombocytopenia, leukopenia).~10. Has heart failure of Class III or IV.~11. Has sensory or motor neuropathy limiting daily activities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMO-8400 at escalating dose levels (Type: EXPERIMENTAL): IMO-8400 at escalating dose levels by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of histologically confirmed classical Hodgkin lymphoma (cHL)~* Limited-stage disease defined as stage I or IIA with no areas of bulky disease~* Measurable disease according to the Cheson criteria~* Age \>=18 years~* Adequate bone marrow reserve (ANC \>= 1,500/uL, Platelet \> 100,000/uL)~* LVEF \>= 50% by MUGA scan or echocardiogram~* Serum creatinine \< 2 mg/dl, serum bilirubin \< 2 mg/dl, AST or ALT \<2x ULN~* Bi-dimensionally measurable disease~* Use of effective means of contraception~* Signed informed consent form~Exclusion Criteria:~* Lymphocyte predominant HL~* Prior chemotherapy or radiation therapy~* Severe pulmonary disease as judged by the PI including COPD and asthma~* Presence of CNS lymphoma~* Concomitant malignancies or previous malignancies (exception made for adequately treated basal or squamous cell carcinoma of the skin)~* Active infection requiring treatment with intravenous therapy~* Known HIV infection~* Active hepatitis B or C~* Pregnancy or lactation and women of child bearing age who are not practicing adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
- ARM B (Type: ACTIVE_COMPARATOR): ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues